Jonathan Baell is Research Professor in medicinal chemistry at Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia. He obtained his Ph.D. in 1992 with Professors Peter Andrews and Paul Alewood. Professor Baell is interested in high throughput screening and the design of better compound libraries, medicinal chemistry hit-to-lead and lead optimization, and computer-aided peptidomimetic design. The ultimate goal is to discover compounds with potential therapeutic utility and of value for the treatment of diseases with current unmet needs. As of 2012, Professor Baell has almost 30 separate patents more than half of which are licensed, and some of his compounds are under current clinical and preclinical development. Disease areas of particular current interest are cancer and infectious diseases. Professor Baell is the principal architect behind Australia’s main collections of >370,000 custom-picked, high-quality small molecule screening compounds selected from vendor catalogues. Professor Baell has won a national medicinal chemistry award and consults widely with the Australian Biotechnology Industry. He is an Editorial Advisory Board Member for Future Medicinal Chemistry and is on the Board of Directors for the Inaugural International Chemical Biology Society. His research projects are design and synthesis of peptidomimetics, medicinal chemistry-led discovery of new antiparasitic compounds for the treatment of malaria, neglected diseases, development of new selection criteria for quality high throughput screening libraries, mechanisms of action of pan assay interference compounds, and hit-to-lead medicinal chemistry applied to epigenetic targets such as histone acetyl transferases.
Biography Updated on 13 September 2012